Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
